{"entity": "publication", "iuid": "0cb94737dbfe4b8784ca738e2b183430", "timestamp": "2026-09-23T15:30:37.579Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/0cb94737dbfe4b8784ca738e2b183430.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/0cb94737dbfe4b8784ca738e2b183430"}}, "title": "Anti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysis.", "authors": [{"family": "Galindo-Feria", "given": "Angeles S", "initials": "AS", "orcid": "0000-0001-7095-211X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7be5528257ac4b4ead8dc05920e0a095.json"}}, {"family": "Lodin", "given": "Karin", "initials": "K"}, {"family": "Horuluoglu", "given": "Begum", "initials": "B"}, {"family": "Sarrafzadeh-Zargar", "given": "Sepehr", "initials": "S"}, {"family": "Wigren", "given": "Edvard", "initials": "E"}, {"family": "Gr\u00e4slund", "given": "Susanne", "initials": "S"}, {"family": "Danielsson", "given": "Olof", "initials": "O"}, {"family": "Wahren-Herlenius", "given": "Marie", "initials": "M", "orcid": "0000-0002-0915-7245", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0db5190dbe894a5e9cd961e66ba5c75d.json"}}, {"family": "Dastmalchi", "given": "Maryam", "initials": "M"}, {"family": "Lundberg", "given": "Ingrid E", "initials": "IE", "orcid": "0000-0002-6068-9212", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a2891140c49d446dbd82c96857bcde73.json"}}, {"family": "SweMyoNet Consortium", "given": "", "initials": ""}], "type": "journal article", "published": "2025-03-01", "journal": {"title": "Rheumatology (Oxford)", "issn": "1462-0332", "volume": "64", "issue": "3", "pages": "1482-1492", "issn-l": "1462-0324"}, "abstract": "To determine prevalence and clinical associations of anti-Four-and-a-half-LIM-domain 1 (FHL1) autoantibodies in patients with idiopathic inflammatory myopathies (IIM) and to evaluate autoantibody levels over time.\n\nSera at the time of diagnosis from patients with IIM (n = 449), autoimmune disease controls (DC, n = 130), neuromuscular diseases (NMDs, n = 16) and healthy controls (HC, n = 100) were analysed for anti-FHL1 autoantibodies by enzyme-linked immunosorbent assay (ELISA). Patients with IIM FHL1+ and FHL1- were included in a longitudinal analysis. Serum levels were correlated to disease activity.\n\nAutoantibodies to FHL1 were more frequent in patients with IIM (122/449, 27%) compared with DC (autoimmune DC and NMD, 13/146, 9%, P < 0.001) and HC (3/100.3%, P < 0.001). Anti-FHL1 levels were higher in IIM [median (IQR)=0.62 (0.15-1.04)] in comparison with DC [0.22 (0.08-0.58)], HC [0.35 (0.23-0.47)] and NMD [0.48 (0.36-0.80)] P < 0.001. Anti-FHL1+ patients with IIM were younger at the time of diagnosis compared with the anti-FHL1- group (P = 0.05) and were seronegative for other autoantibodies in 25%.In the first follow-up, anti-FHL1+ sample 20/33 (60%) positive at baseline had turned negative for anti-FHL1 autoantibodies. Anti-FHL1 autoantibodies rarely appeared after initiating treatment. Anti-FHL1 autoantibody levels correlated with CK (r = 0.62, P= 0.01), disease activity measured using the Myositis Disease Activity Assessment Tool (MYOACT) (n = 14, P = 0.004) and inversely with Manual Muscle Test-8 (r = -0.59, P = 0.02) at baseline.\n\nAnti-FHL1 autoantibodies were present in 27% of patients with IIM; of these, 25% were negative for other autoantibodies. Other autoimmune diseases had lower frequencies and levels. Anti-FHL1 levels often decreased with immunosuppressive treatment, correlated with disease activity measures at diagnosis and rarely appeared after start of treatment.", "doi": "10.1093/rheumatology/keae317", "pmid": "38833674", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11879316"}, {"db": "pii", "key": "7687810"}], "notes": [], "created": "2026-09-23T12:29:22.344Z", "modified": "2026-09-23T12:29:22.372Z"}